https://mounjaronews.info/en/Recent content in Mounjaro Info on mounjaro/news — Tirzepatide watchHugoen-UShttps://mounjaronews.info/en/about/Mon, 01 Jan 0001 00:00:00 +0000https://mounjaronews.info/en/about/<h2 id="what-is-mounjaro-info">What is Mounjaro Info?</h2> <p><strong>Mounjaro Info</strong> is an independent information website dedicated to <strong>Mounjaro (tirzepatide)</strong>, a medication developed by Eli Lilly. Our mission: making medical and scientific information about tirzepatide accessible in French, English and Traditional Chinese.</p> <h2 id="tirzepatide-at-a-glance">Tirzepatide at a glance</h2> <p>Tirzepatide is a <strong>dual GIP and GLP-1 receptor agonist</strong>, a new class of medication that acts on two hormonal pathways to:</p> <ul> <li>Improve glycemic control in type 2 diabetes patients</li> <li>Promote significant weight loss</li> <li>Reduce cardiovascular risk factors</li> </ul> <h3 id="regulatory-approvals">Regulatory approvals</h3> <ul> <li><strong>FDA</strong> (United States): approved May 2022 for type 2 diabetes</li> <li><strong>EMA</strong> (Europe): approved September 2023</li> <li><strong>Zepbound</strong>: weight management formulation (FDA, November 2023)</li> </ul> <h2 id="our-approach">Our approach</h2> <p>Every day, we collect the latest news, clinical studies and developments related to tirzepatide. This information is:</p>https://mounjaronews.info/en/contact/Mon, 01 Jan 0001 00:00:00 +0000https://mounjaronews.info/en/contact/